DEXCOM INC (DC4.DE) Stock Fundamental Analysis

FRA:DC4 • US2521311074

63.03 EUR
+1.97 (+3.23%)
Last: Feb 23, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Taking everything into account, DC4 scores 6 out of 10 in our fundamental rating. DC4 was compared to 65 industry peers in the Health Care Equipment & Supplies industry. While DC4 has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, DC4 is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year DC4 was profitable.
  • DC4 had a positive operating cash flow in the past year.
  • DC4 had positive earnings in 4 of the past 5 years.
  • Of the past 5 years DC4 4 years had a positive operating cash flow.
DC4.DE Yearly Net Income VS EBIT VS OCF VS FCFDC4.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

1.2 Ratios

  • DC4's Return On Assets of 9.61% is amongst the best of the industry. DC4 outperforms 89.23% of its industry peers.
  • With an excellent Return On Equity value of 26.44%, DC4 belongs to the best of the industry, outperforming 93.85% of the companies in the same industry.
  • DC4 has a better Return On Invested Capital (15.72%) than 95.38% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for DC4 is in line with the industry average of 9.73%.
  • The last Return On Invested Capital (15.72%) for DC4 is above the 3 year average (11.25%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.61%
ROE 26.44%
ROIC 15.72%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
DC4.DE Yearly ROA, ROE, ROICDC4.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

  • DC4 has a Profit Margin of 15.96%. This is amongst the best in the industry. DC4 outperforms 90.77% of its industry peers.
  • In the last couple of years the Profit Margin of DC4 has grown nicely.
  • Looking at the Operating Margin, with a value of 18.41%, DC4 is in the better half of the industry, outperforming 78.46% of the companies in the same industry.
  • In the last couple of years the Operating Margin of DC4 has grown nicely.
  • DC4's Gross Margin of 60.20% is in line compared to the rest of the industry. DC4 outperforms 56.92% of its industry peers.
  • In the last couple of years the Gross Margin of DC4 has remained more or less at the same level.
Industry RankSector Rank
OM 18.41%
PM (TTM) 15.96%
GM 60.2%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
DC4.DE Yearly Profit, Operating, Gross MarginsDC4.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • DC4 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • DC4 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DC4.DE Yearly Shares OutstandingDC4.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
DC4.DE Yearly Total Debt VS Total AssetsDC4.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • DC4 has an Altman-Z score of 5.22. This indicates that DC4 is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of DC4 (5.22) is better than 87.69% of its industry peers.
  • The Debt to FCF ratio of DC4 is 2.36, which is a good value as it means it would take DC4, 2.36 years of fcf income to pay off all of its debts.
  • DC4 has a better Debt to FCF ratio (2.36) than 75.38% of its industry peers.
  • DC4 has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
  • DC4 has a Debt to Equity ratio of 0.47. This is comparable to the rest of the industry: DC4 outperforms 50.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 2.36
Altman-Z 5.22
ROIC/WACC1.66
WACC9.45%
DC4.DE Yearly LT Debt VS Equity VS FCFDC4.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

  • DC4 has a Current Ratio of 1.56. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of DC4 (1.56) is comparable to the rest of the industry.
  • DC4 has a Quick Ratio of 1.38. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.38, DC4 is in the better half of the industry, outperforming 66.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 1.38
DC4.DE Yearly Current Assets VS Current LiabilitesDC4.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • DC4 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.67%, which is quite impressive.
  • Measured over the past years, DC4 shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.10% on average per year.
EPS 1Y (TTM)26.67%
EPS 3Y33.93%
EPS 5Y22.1%
EPS Q2Q%51.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.12%

3.2 Future

  • Based on estimates for the next years, DC4 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.26% on average per year.
  • The Revenue is expected to grow by 12.21% on average over the next years. This is quite good.
EPS Next Y20.81%
EPS Next 2Y20.72%
EPS Next 3Y21.95%
EPS Next 5Y19.26%
Revenue Next Year12.81%
Revenue Next 2Y12.84%
Revenue Next 3Y13.05%
Revenue Next 5Y12.21%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
DC4.DE Yearly Revenue VS EstimatesDC4.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
DC4.DE Yearly EPS VS EstimatesDC4.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 35.41, DC4 can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of DC4 is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Earnings ratio of 26.64, DC4 is valued a bit more expensive.
  • Based on the Price/Forward Earnings ratio of 29.38, the valuation of DC4 can be described as expensive.
  • 63.08% of the companies in the same industry are cheaper than DC4, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.75, DC4 is valued at the same level.
Industry RankSector Rank
PE 35.41
Fwd PE 29.38
DC4.DE Price Earnings VS Forward Price EarningsDC4.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DC4 is valued a bit more expensive than 66.15% of the companies in the same industry.
  • 64.62% of the companies in the same industry are more expensive than DC4, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 27.24
EV/EBITDA 24.11
DC4.DE Per share dataDC4.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of DC4 may justify a higher PE ratio.
  • DC4's earnings are expected to grow with 21.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.7
PEG (5Y)1.6
EPS Next 2Y20.72%
EPS Next 3Y21.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • DC4 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DEXCOM INC

FRA:DC4 (2/23/2026, 7:00:00 PM)

63.03

+1.97 (+3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners99.77%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap24.58B
Revenue(TTM)N/A
Net Income(TTM)720.70M
Analysts84.32
Price Target75.05 (19.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.05%
Min EPS beat(2)5.32%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-0.91%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)4.61%
EPS beat(12)10
Avg EPS beat(12)13.69%
EPS beat(16)11
Avg EPS beat(16)6.53%
Revenue beat(2)2
Avg Revenue beat(2)0.74%
Min Revenue beat(2)0.61%
Max Revenue beat(2)0.88%
Revenue beat(4)2
Avg Revenue beat(4)0.02%
Min Revenue beat(4)-1.2%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.92%
Revenue beat(12)5
Avg Revenue beat(12)-0.38%
Revenue beat(16)6
Avg Revenue beat(16)-0.58%
PT rev (1m)7.73%
PT rev (3m)-3.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.07%
EPS NY rev (1m)0.09%
EPS NY rev (3m)-0.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE 35.41
Fwd PE 29.38
P/S 6.41
P/FCF 27.24
P/OCF 19.98
P/B 10.61
P/tB 11.03
EV/EBITDA 24.11
EPS(TTM)1.78
EY2.82%
EPS(NY)2.15
Fwd EY3.4%
FCF(TTM)2.31
FCFY3.67%
OCF(TTM)3.16
OCFY5.01%
SpS9.84
BVpS5.94
TBVpS5.72
PEG (NY)1.7
PEG (5Y)1.6
Graham Number15.42
Profitability
Industry RankSector Rank
ROA 9.61%
ROE 26.44%
ROCE 19.96%
ROIC 15.72%
ROICexc 77.75%
ROICexgc 88.6%
OM 18.41%
PM (TTM) 15.96%
GM 60.2%
FCFM 23.51%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexgc growth 3Y55.18%
ROICexgc growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score5
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 2.36
Debt/EBITDA 1.2
Cap/Depr 158.02%
Cap/Sales 8.55%
Interest Coverage 250
Cash Conversion 134.63%
Profit Quality 147.34%
Current Ratio 1.56
Quick Ratio 1.38
Altman-Z 5.22
F-Score5
WACC9.45%
ROIC/WACC1.66
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)26.67%
EPS 3Y33.93%
EPS 5Y22.1%
EPS Q2Q%51.11%
EPS Next Y20.81%
EPS Next 2Y20.72%
EPS Next 3Y21.95%
EPS Next 5Y19.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.12%
Revenue Next Year12.81%
Revenue Next 2Y12.84%
Revenue Next 3Y13.05%
Revenue Next 5Y12.21%
EBIT growth 1Y28.95%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year73.63%
EBIT Next 3Y36.37%
EBIT Next 5Y30.37%
FCF growth 1Y112.47%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y93.75%
OCF growth 3Y30.77%
OCF growth 5Y25.76%

DEXCOM INC / DC4.DE FAQ

What is the ChartMill fundamental rating of DEXCOM INC (DC4.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to DC4.DE.


What is the valuation status for DC4 stock?

ChartMill assigns a valuation rating of 3 / 10 to DEXCOM INC (DC4.DE). This can be considered as Overvalued.


Can you provide the profitability details for DEXCOM INC?

DEXCOM INC (DC4.DE) has a profitability rating of 8 / 10.


How financially healthy is DEXCOM INC?

The financial health rating of DEXCOM INC (DC4.DE) is 6 / 10.


Can you provide the expected EPS growth for DC4 stock?

The Earnings per Share (EPS) of DEXCOM INC (DC4.DE) is expected to grow by 20.81% in the next year.